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T2*Cardiac damage remains a major cause of mortality among patients with thalassemia major. The detection of a
lower cardiac magnetic resonance T2* (CMR-T2*) signal has been suggested as a powerful predictor of the subse-
quent development of heart failure. However, the lack of worldwide availability of CMR-T2* facilities prevents its
widespread use for follow-up evaluations of cardiac function in thalassemia major patients, warranting the need
to assess the utility of other possible procedures. In this setting, the determination of left ventricular ejection fraction
(LVEF) offers an accurate and reproduciblemethod for heart function evaluation. These ﬁndings suggest a reduction
in LVEF≥7%, over time, determined by 2-D echocardiography, may be considered a strong predictive tool for the
detection of thalassemiamajor patients with increased risk of cardiac death. The reduction of LVEF≥7% had higher
(84.76%) predictive value. Finally, Kaplan–Meier survival curves of thalassemia major patients with LVEF≥7%
showed a statistically signiﬁcant decreased probability of survival for heart disease (p=0.0022).
However, because of limitations related to the study design, such ﬁndings should be conﬁrmed in a large
long-term prospective clinical trial.
© 2012 Elsevier Inc. All rights reserved.Introduction
Thalassemia is one of themost common genetic diseasesworldwide,
with at least 60,000 severely affected subjects being born every year [1].lassemia”, A.O. ‘V.Cervello’, Via
8.
mo.it (A. Maggio).
rights reserved.The prognosis for thalassemia major has dramatically improved during
the last three decades [2,3]. Transfusions and the availability of different
iron chelators are the main reasons for signiﬁcantly increased survival
and reduced morbidity in this population [4–6].
Despite these positive advances, many transfusion-dependent
patients continue to develop tissue damage, mainly from tissue iron
accumulation, putting them at risk of premature death, particularly
from cardiac disease. Heart complications remain a major cause of
Retrospective study of 
413 thalassemia major  
patients
Included : 188
Excluded: 225*
188 included  
patients
The deceased
group: 22 
Allocated and analysed: The alive 
group: 166 
* 189 younger than 15 years of age and 36 lost at the follow-up
Fig. 1. Trial proﬁle of the deceased group versus the alive group during the study.
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cardiac failure occurs in 6–10% of these patients [5,6,8].
The combination of iron-mediated toxicity [9] with increased car-
diac output [10] is associated with the development of heart failure.
In recent years, several methods of detecting tissue iron content have
been developed [11]. Among these methods, the Cardiac Magnetic
Resonance T2* parameter (CMR-T2*) [12] is a powerful predictor of
the subsequent development of heart failure, especially for cardiac
T2* valuesb7 ms [13]. Recently, Marsella et al. [14], studying a
large cohort of thalassemia major patients, showed that only 9% of
men and 3% of women with CMR-T2* above 20 ms had cardiac dys-
function. Moreover, a statistical signiﬁcant difference in CMR-T2*
was shown between patients with normal and abnormal cardiac
functions (pb0.0001) [14].
However, the lack of worldwide availability of CMR-T2* facilities
is a crucial limitation preventing its widespread use for annual
follow-up evaluations of cardiac function in thalassemia major
patients [15]. Actually, Thalassemia International Federation (TIF),
involving an umbrella of 109 national thalassemia associations
worldwide, pointed out that only 19/55 countries use the cardiac
validated MRI T2* software (personal communication). This, in most
of the cases, does not allow access to the majority of patients but only
to a portion of the patients that are around the centers where
CMR-T2* is available.
The limited availability of CMR-T2* facilities worldwide [15]
warrants the more widespread adoption of effective and accessible
tools for the detection of thalassemia major patients at risk of
heart failure. The determination of Left Ventricular Ejection Fraction
(LVEF) by echocardiography is considered to be a reliable and wide-
ly used tool to evaluate heart function. The worldwide availability of
echocardiography is also greater than that of CMR-T2*. RecentTable 1
Findings at the start among the 188 patients included in the trial.
Findings Deceased-groupa
No pts (188) 22
Females (%) 11 (50.00)
Treatment 1 pt Sequential DFO–DFP, 21 pts DFO
Age in years 29±7.52
Hgb, g/la 9.87±0.55
ALT, IU/la 71.37±36.52
LIC, mg/g/dw 7272.5±11,107.74
Total blood transfusion, ml/kg/year 9007.18±2169.16
Mean ferritin, μg/l 2413.5±1497.12
Mean basal LVEFb55% (no) 46.78±7.32 (9)
Mean age at DFO starting, years 8.68±1.14
Splenectomy (%) 16 (72.72)
Cirrhosis (%) 8 (36.36)
Arrhythmia (%) 10 (45.45)
HCV-RNA positive (%) 15 (68.18)
a All patients died for cardiac diseases, particularly, 19 for left heart failure, 2 for right hestudies have shown acceptable interobserver and intraobserver
reproducibility values of the echocardiographic evaluation of left
ventricular ejection fraction [16,17], similar to that of CMR, even
in patients with thalassemia major [18]. Otterstad et al. [19]
conﬁrmed that 2-D echocardiography measurements of LVEF are
more accurate and reproducible if determination is performed by
a single operator, as was performed in our study. For all these
reasons regular monitoring of LVEF in thalassemia major patients
has been strongly recommended [20] and should be included in
any service with the responsibility of care for thalassemia major
patients.
The main aim of this study was to evaluate whether variations in
LVEF values over time could be used as a predictive tool in the risk
assessment of cardiac death in thalassemia major patients.
Materials and methods
Patients
This report describes a retrospective study of 413 patients with
thalassemia major who were managed from January 31, 1980 to
January 31, 2008. Age was measured as difference between death
versus born year among deceased patients, while as difference between
January 31, 2008 versus born year for alive patients. A complete LVEF
record was deﬁned as at least 1 complete echocardiography each year
for at least four consecutive years in patients older than 15 years and
without any clinical evidence of cardiac disease. Among the 413 ob-
served patients, 188 had complete records for serial observations of
LVEF measurements for at least four consecutive years (Fig. 1). The
remaining patients were excluded either because they were younger
than 15 years at January 31, 1980 or because they were lost at the
follow-up (Fig. 1). The census for alive and not-alive group was taken
during the follow-up period. The median of this was 8.5 years. All
deaths considered in this study were due to cardiac disease (Table 1).
The diagnosis of heart disease was based on standard clinical and in-
strumental ﬁndings including echocardiography and electrocardiogram
[20]. Findings, reported on Table 1, refer to the year of patient's ﬁrst
observation. Patients that stabilize their LVEF by taking cardiac drugs
or that, after an initial decrease, had a subsequent increase of LVEF are
still now alive. Their LVEF improved gradually and only three are still
receiving Ace-inhibitor treatment.
Method
LVEF is deﬁned as the fraction of end-diastolic volume that is
ejected by the left ventricle in each beat. It was measured by a single
operator with two-dimensional (2-D) echocardiography assessmentsAlive-group p-Value
166
85 (51.21) 0.93
84 pts DFO, 47 pts DFP, 35 Sequential DFO–DFP
32±8.66 0.11
9.08±0.81 0.0005
48.51±39.33 0.0438
3014.58±3257.67 0.0329
8829.55±2471.06 0.782
1505.95±785.53 b0.0001
47.52±8.74 (19) 0.945
5.54±0.41 0.017
72 (43.37) 0.0336
9 (5.42) 0.11
23 (13.85) 0.0489
47 (28.31) 0.0056
art failure and 1 for arrhythmia due to ventricular ﬁbrillation.
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Red=Deceased-group
46
48
50
52
54
56
58
60
62
64
LV
EF
 %
0 1 2 3 4
Years
Fig. 2. Estimated proﬁles from the ﬁtted GEE model for the two patient-groups: the
deceased versus the alive-group.
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patient (Vivid S5, Gems Ultrasound, Tirat Carmel, Israel).
Two-dimensional echocardiography was used for determination of
the left ventricular ejection fraction and volumes (single plane area-
length method), and for calculation of right ventricular end-diastolic
and end-systolic areas by planometry from the four-chamber view,
according to previous recommendations [21]. Patient baseline clinical
ﬁndings were reported with means and standard deviations (SD) for
continuous variables and as proportions for dichotomous variables.
LIC was determined on liver biopsies by atomic spectrophotometer.
Liver biopsy was performed only in patients included in interferon
treatment for chronic C hepatitis.
Statistical models
The generalized estimating equations (GEE) model was used [22]
to evaluate if the variation of LVEF over time (four consecutive
years) was statistically signiﬁcant different between alive versus not
alive patients.
Actually, LVEF values consisted of repeated observations over time
on the same patient. These measurements, taken on the same patient,
may not be independent one from another. In this context, one of the
appropriate models, taking into account for the issue that repeated
measurements might be correlated, is the generalized estimating
equations (GEE) model [22], which results to be more reliable inTable 2
Findings found after categorizing the average changing of LVEF in three different levels (ba
Findings Baseline 1-Categ
Deceased-group Alive-group p-Value Decease
No pts (188) 5 77 6
Females (%) 2 (20) 37 (48.1) 0.44 4 (66.6
Age in years 28.6±9.1 31.8±10 0.48 31.6±7
Hgb, g/la 9.6±0.4 9.03±0.7 0.18 9.8±0.
ALT, IU/la 65.8±37.3 44.1±38.5 0.24 94.4±6
Total blood transfusion,ml/kg/year 7408.3±
21,764.3
8196.7±
2392.2
0.58 10,575
Mean ferritin, μg/l 1887.6±1499.3 1548.7±687.4 0.35 1985.6
Basal mean ejection fraction 45.6±10.5 56.9±7.7 0.025 60±2.2
Mean age at DFO starting, years 10.2±2.5 6.1±5.9 0.16 8.5±7.
Splenectomy (%) 3 (60) 35 (45.4) 0.61 3 (60)
Cirrhosis (%) 1 (20) 5 (6.5) – 1 (20)
Arrhythmia (%) 3 (60) 13 (16.8) 0.11 2 (20)
HCV-RNA positive (%) 3 (60) 17 (22.6) 0.18 3 (60)
a This table does not describe “a priori” different groups based on their quantitative variab
the time.comparison with evaluation of single temporal ﬁnding by Student t
test. In the GEE model, status-effect (status), time-effect (time) and
status-by-time interaction effect (status× time) were considered.
This approach was implemented using the ‘xtgee’ procedure in the
Stata 11 software (Stata Corporation, College Station, TX, USA).
Because the GEE model pointed out a statistically signiﬁcant
difference in the variation of LVEF over time between alive versus
not alive patients (Fig. 2, Table 3), a logistic regression model was
used to evaluate the risk of death from heart disease on the basis of
the mean variations in LVEF (Table 4). Therefore, the mean variations
in LVEF values were categorized into three levels: 1) the baseline cat-
egory, including all patients with an increase in mean of LVEF≥0%; 2)
the 1-category, including all patients with a reduction in mean of
LVEF between 0% and 7%; and 3) the 2-category, including all patients
with a reduction in mean LVEF≥7% (Table 2). The choice of 7% was
based on a paper by Kalogeropoulos et al. [23], which assessed LVEF
determination using 2-D echocardiography and suggested 7% as the
amount of variability for test–retest measurement with a 95% agree-
ment. ROC curve was used for assessing a prognostic value of δ
LVEF, calculated as the difference between the initial and ﬁnal values
of LVEF [24]. The sensitivity and speciﬁcity of delta LVEF, based for
values of LVEF≥7%, were also calculated [24]. Survival curves
among baseline, 1-category and 2-category were estimated using
the Kaplan–Meier method and the survival among groups were com-
pared with the log-rank test [24]. All of the statistical analyses were
performed by A.V.
Results
Demographic ﬁndings of patients in both groups are shown in
Table 1. Among the 188 analyzed patients, 166 were alive. Among the
22-deceased cohort, 21 patients were being treated with deferoxamine
alone treatment (DFO), while 1 received sequential treatment of
deferoxamine (DFO) and deferiprone (DFP) (Table 1) [25]. In the alive
cohort 84 patients received DFO-alone, 47 DFP-alone and 35 DFO–
DFP-sequential chelation treatment regimens (Table 1). The number of
patients with a mean basal LVEFb55% was not statistically different be-
tween the two groups (Table 1). On the other hand, patients in the de-
ceased cohort had statistically signiﬁcant higher LIC and serum ferritin
levels compared with the alive group (Table 1). Moreover, a statistically
signiﬁcant difference was found between the two groups regarding
mean levels of Hb (g/l), mean age at starting chelation treatment, sple-
nectomy, arrhythmia (%) and HCV-RNA positivity (%) (Table 1). The
deceased, included in this trial, died for heart disease (Table 1). The pro-
portions of patients in the alive and deceased cohorts, categorized into
the three LVEF categorized groups are shown in Table 2. Fig. 2 showsseline, 1 and 2) a.
ory 2-Category
d-group Alive-group p-Value Deceased-group Alive-group p-Value
61 11 28
) 37 (0.6) 0.81 5 (45.5) 11 (0.39) 0.82
.9 31.3±7.3 0.89 27.5±6.8 34.1±7.0 0.0124
6 8.9±0.7 0.01 10.1±0.6 9.4±1.0 0.13
4.3 56.9±44.2 0.11 94.7±47.6 42.5±29.2 0.0016
±2467.6 9035.1±
2336.3
0.21 8843.3±1882.3 10,154.3±
2462.1
0.15
±1508.8 1728.9±963.2 0.6 2890.4±1555.7 1549.2±694.8 0.0022
63.7±5.4 0.09 55.9±8.1 71.5±5.6 b0.0001
2 4.7±3.6 0.06 8±4.3 5.9±4.4 0.25
27 (46.5) 0.64 10 (27.1) 10 (90.9) 0.0037
2 (3.4) – 4 (40) 2 (7.1) 0.4026
6 (9.8) 0.7 5 (45.5) 4 (14.3) 0.3173
21 (35) 0.4 9 (81.8) 9 (32.1) 0.0332
le differences but ﬁndings found after categorizing the average changing of LVEF during
Table 3
GEE model to evaluate changes in mean ejection fraction levels in deceased-group ver-
sus alive-group over time.
Coefﬁcients (SE⁎) 95% CI⁎ p-Value⁎
Intercept 60.89 (0.61) (59.69; 62.09) b0.0001
Status⁎⁎ −6.58 (1.78) (−10.08; −3.07) b0.0001
Year⁎⁎ 0.27 (0.13) (−0.001; 0.54) 0.051
Status×year⁎⁎ −1.51 (0.41) (−2.31; −0.71) b0.0001
SE⁎=Standard Error, CI⁎=Conﬁdence Interval, p-value⁎ from null hypothesis coefﬁ-
cient=0 by Wald's test.
Status⁎⁎ is the variable indicating if a patient is dead or alive; Year⁎⁎ is the variable
indicating the consecutive years of observation, corresponding to t=0, 1, 2, 3, 4;
Status×Year⁎⁎ is a status-by-time interaction effect.
0.
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Fig. 3. ROC curve showing sensitivity and speciﬁcity of δ LVEF in detecting TM patients
at risk of death for cardiac disease.
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based on the ﬁtted GEE model. The regression coefﬁcient of status×year
suggested a statistically signiﬁcant linear decrease over time of LVEF
values among the deceased patients (Coeff. −1.51, 95% CI (−2.31–
0.71), p-valueb0.0001, Table 3 and Fig. 2) compared with the alive
ones. Actually, the alive cohort had increased LVEF values over time,
although this result determination in detecting was not statistically sig-
niﬁcant (Coeff. 0.27, 95% CI (−0001; 0.54), p-value=0.051, Table 3 and
Fig. 2). The risk of death due to cardiac failure in patients with a mean
reduction of LVEF≥7% was 4.93, with a 95% conﬁdence interval (CI) of
1.61 to 15.11 (p-value=0.005, Table 4). The median time from the last
echocardiography to death was 3 years. Falls in LVEF between 0% and
7% were not associated with statistically signiﬁcant risk of death for
heart disease (OR=1.22, p-value=0.762, Table 4). No statistically signif-
icant correlation was found between the δ LVEF and serum ferritin levels
(r=−0.11; p=0.22). The area under the ROC curve was 70.33% (Fig. 3).
The sensitivity and speciﬁcity of δ LVEF were 84.76% and 40.91%, respec-
tively (Fig. 3). Fig. 4 shows the Kaplan–Meier survival curves concerning
the three considered different categories of thalassemia major patients.
Finally, to see if LVEF represented a stronger prognostic marker than
other laboratory and instrumental variables, a multivariate analysis at
baseline for LVEF at baseline, serum ferritin levels and LIC was
performed. All these variables were matched with probability of death.
No statistically signiﬁcant result was obtained by this analysis.0.75
1.00
ba
bi
lit
yDiscussion
These ﬁndings suggest a reduction in LVEF≥7%, over time, deter-
mined by 2-D echocardiography, may be considered a strong predictive
tool for the detection of thalassemia major patients with increased risk
of death due to cardiac disease (Fig. 2, Table 3).Moreover, the reduction
in LVEF≥7% showed high sensitivity (84.76%) in predicting increased
risk of death due to cardiac disease (Fig. 3). Finally, as it is shown by
the Kaplan–Meier survival curves (Fig. 4), thalassemia major patients
included in category 2 showed a statistically signiﬁcant decrease of
survival probability for cardiac disease in comparison with baselineTable 4
Logistic regression model indicated an effect of the mean reduction of ejection fraction
on risk of death for heart disease.
OR⁎ (SE⁎) 95% CI⁎ p-Value
MVLVEF1⁎⁎ 1.22 (0.81) (0.33; 4.41) 0.762
MVLVEF2⁎⁎ 4.93 (2.81) (1.61; 15.11) 0.005
OR⁎=Odds Ratio, SE⁎=Standard Error, CI⁎=Conﬁdence Interval.
MVLVEF1⁎⁎ is the 1-category of the mean variation of LVEF variable including all
patients with a mean reduction of ejection fraction greater than 0% and less than 7%.
MVLVEF2 ⁎⁎ is the 2-category of the mean variation of LVEF variable including all
patients with a mean reduction of ejection fraction greater or equal to 7%.and 1-category group, respectively (p=0.0022). The detection of 2/22
deaths from right ventricular failure (Table 1) could be explained by
the presence, in these patients, of a biventricular cardiomyopathy,
reported on thalassemia major patients [26]. Moreover, sudden ar-
rhythmic death is recognized as the cause of death in from 30% to 50%
of patients with heart failure. Furthermore, it has been demonstrated
that implantation of ICD (Intracardiac Deﬁbrillator) is effective in
reducing mortality through prevention of sudden arrhythmic death, in
patients with mild or moderate dysfunction (II or III NYHA class) [27].
This could be the reason for the single death due to ventricular ﬁbrilla-
tion among our patients (Table 1). The mean of LVEF at 1 year from the
follow-up in patients with >7% change in LVEF was 63±3%.
Relying on LVEF values in themanagement of heart failure in thalas-
semia major patients has been stressed in several previous papers.
Davis et al. [28] reported ﬁndings concerning eighty-one patients with
thalassemiamajor but no history of cardiac diseasewho received quan-
titative annual LVEFmonitoring by radionuclide ventriculographyusing
multigated acquisition (MUGA) for amedian of 6.0 years (inter-quartile
range, 2–12 years) [28]. An absolute LVEF decrease ofmore than10per-
centage units was signiﬁcantly associated with subsequent develop-
ment of symptomatic cardiac disease (pb .001) and death (p=.001),
with a median interval between the ﬁrst abnormal LVEF ﬁndings and*p-value from log-rank test
0.00
0.25
0.50
0 5 10 15 20 25
Time since observation
Baseline category 1 category 2 category
*p-value=0.002
Su
rv
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Fig. 4. Kaplan–Meier curves for cardiac disease mortality in the three categorized
thalassemia major groups.
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what was found in this paper [28]. Moreover, Davis et al. [28] reported
that LVEF changes were demonstrable before cardiac symptoms
appeared in all patients except 1 [28]. Furthermore, studies reporting
on the use of chelators in treating transfusional iron overload have
raised interesting questions regarding cardiac performance associated
with changes in mean LVEF values of thalassemia major patients. Stud-
ies of thalassemiamajor patients during heart failure with severe cardi-
ac siderosis and decreased LVEF have shown that a combined treatment
of deferiprone and deferoxamine increased mean absolute cohort LVEF
values by 14% over 1 year [29], while treatment with continuous intra-
venous deferoxamine raised LVEF by 11% [30]. Recently, Pennell et al.
[31] hypothesized that small increases in LVEF among thalassemia
major patients would be expected to reduce the risk of heart failure.
Changes in LVEF (3.1% vs. 2.6%), as compared with CMR-T2* during
DFP-alone or combination DFP-DFO treatment, were associated with
risk reduction for the development of heart failure over 12 months
(46.4% vs. 25.5%, respectively) [31]. However, the actual risk for heart
failure, in this paper, remains very small. Recently, a multicenter ran-
domized open-label long-term sequential deferiprone–deferoxamine
(DFP–DFO) versus DFP alone trial, performed in patients with thalasse-
mia major, was retrospectively reanalyzed to assess the variation in the
LVEF [32]. The DFP-alone group showed statistically signiﬁcant increase
over time in mean LVEF in comparison with sequential DFO-FP
treatment (coefﬁcient 0.97, 95% CI (0.51; 1.44), p-valueb0.0001) [32].
These ﬁndings, obtained by 2D-echocardiography assessment [30] are
very similar to those reported by Pennell et al. [31] using CMR-T2*.
Although the use of CMR-T2* has a main role in managing thalasse-
mia major, the limited availability of CMR-T2* facilities worldwide [15]
warrants the more widespread adoption of effective and accessible
tools for the detection of thalassemiamajor patients at risk of cardiac dis-
ease. As it is well known, theworldwide availability of echocardiography
is greater. Although, concerns remain regarding the reliability of echo-
cardiography in determining LVEF [16–20], the use of echocardiographic
equipmentwith advanced technology in combinationwith implementa-
tion of harmonic imagingmay enhance detection of endocardial borders
with more accurate determination of LVEF [33].
In conclusion, this retrospective survey suggests that variations in
LVEF values over time, as determined by 2D-echocardiography, may
be used for risk assessment of heart failure in patients with thalassemia
major. However, because of limitations related to the study design, such
ﬁndings should be conﬁrmed in a large long-term prospective clinical
trial.
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